Cefdinir

Drug Profile

Cefdinir

Alternative Names: BMY 28488; Cefzon; Cefzon Capsule; CI 983; FK 482; FR 80482; Omnicef; PD 134393

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Developer AbbVie; Astellas Pharma; JE II Pharmaceutical; Valeant Pharmaceuticals International
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Bacterial infections; Otitis media; Otorhinolaryngological infections; Pneumonia; Respiratory tract infections; Skin and soft tissue infections

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 11 Dec 2012 Valeant Pharmaceuticals acquires Medicis Pharmaceutical Corporation
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top